Ulcerative Colitis

See the results from our Phase 2 open-label clinical trial in ulcerative colitis here.

PHOTO_Clinical Trials_Lung Cancer

Do you have ulcerative colitis?

Reversing Chronic Inflammation Underlying Ulcerative Colitis

There is growing evidence that defect or suppression of the innate immune system may underlie a variety of immune-related diseases, including ulcerative colitis. Qu Biologics is developing Site Specific Immunomodulators (SSIs), designed to restore the body’s normal immune response. In the case of ulcerative colitis, QBECO SSI, derived from components of inactivated E. coli, is designed to restore innate immune function in the colon and reverse the chronic inflammation and dysbiosis associated with the disease. Read more about how SSIs restore normal immune function.



Qu Biologics’ clinical trial in ulcerative colitis

Qu Biologics has completed a Phase 2 open-label clinical trial in ulcerative colitis.  A summary of the results from this Health Canada-approved trial can be found here.

If you are interested in keeping up to date on the status of Qu Biologics’ clinical research into ulcerative colitis, you may sign up to receive updates.

If at any time you have any questions, you may email ulcerativecolitis@quibd.com.

Join our IBD Community Advisory Panel

If you are someone living with inflammatory bowel disease or are a caregiver, we’d like to hear from you! You could make a difference in how our clinical trials are designed. Learn more about joining our IBD Community Advisory Panel.

For more information on our clinical program in ulcerative colitis visit www.quibd.com.